ProCE Banner Activity

Phase I Study of Patritumab Deruxtecan in Patients With EGFR-Mutated NSCLC and Resistance to EGFR TKI Therapy

Slideset Download
Conference Coverage
Updated phase I results with extended follow-up show antitumor activity of patritumab deruxtecan in patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC across various EGFR TKI resistance mechanisms and regardless of prior therapy or presence of CNS metastases.

Released: June 08, 2021

Expiration: June 07, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Amgen, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.


Gilead Sciences, Inc.


Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme